Funding opportunity

Funding opportunity: Prosperity partnerships: advanced therapies safety and toxicity

Apply for funding to support emerging or established research partnerships between businesses and academic partners (lead must be UK-based).

Co-developed programmes should focus on the safety and toxicity of advanced therapies, developing tools and resources to assess and mitigate safety risks. The research will integrate discovery and translational science, aiming to propel future advanced therapies into clinics.

Multiple academic and business partners can participate, with MRC funding academic costs of £2 million to £4 million Full Economic Cost (FEC) for up to five years. Equal contribution is expected by the business partner(s).

You must be invited to apply.

Who can apply

To apply for this funding opportunity, you must have completed the mandatory expression of interest stage (that closed on 6 November 2024) and have been invited to this full stage of the funding opportunity. See ‘how to apply’ for more information.

Applications must be co-developed and led by an academic lead (project lead in the UK Research and Innovation (UKRI) Funding Service) and a lead business project partner (the primary business partner in the partnership).

Who is eligible to apply

Research organisations can act as the academic lead if they are eligible to receive UKRI funding.

Businesses can act as the lead project partner if they are:

  • a UK-based business or have UK-based research activity
  • a business in the private sector driven by profit, or from an organisation with a commercial arm which generates independent revenue
  • able to contribute to the UK national prosperity through increasing their investment in research and development activities and subsequent product, service, or technology development in the UK

Businesses may be a contributor to other applications as a project partner. Other businesses can collaborate in the partnership as project partners, but the majority of the matched contribution is expected from the lead business partner.

Before applying for funding, check the Eligibility of your organisation.

UKRI has introduced new role types for funding opportunities being run on the new Funding Service.

For full details, visit Eligibility as an individual.

A research organisation may lead or partner on more than one application and applications may comprise more than one research organisation.

For applicants who do not have a contract of employment for the duration of the proposed programme, by submitting an application the research organisation is confirming, if it is successful:

  • contracts will be extended beyond the end date of the programme
  • all necessary support for the programme and the applicants will be provided, including mentorship and career development for early career researchers

The application must also be codeveloped by a minimum of one ‘business’ lead/ partner. Businesses can act as the lead project partner if they are:

  • a UK-based business or have UK-based research activity
  • a business in the private sector driven by profit, or from an organisation with a commercial arm which generates independent revenue
  • able to contribute to the UK national prosperity through increasing their investment in research and development activities and subsequent product, service, or technology development in the UK

Businesses may be a contributor to other applications as a project partner. Other businesses can collaborate in the partnership as project partners, but the majority of the matched contribution is expected from the lead business partner.

Who is not eligible to apply

You are not eligible to apply for this funding opportunity as a lead if you are based at an international research organisation. This does not include MRC Unit The Gambia or MRC/UVRI Uganda Research Unit at the London School of Hygiene and Tropical Medicine that are eligible to apply as project lead. Before applying for funding, check the Eligibility of your organisation.

International applicants

You can include international applicants as programme co-leads (international), where they will make a major intellectual contribution to the design or conduct of the programme. The contribution and added value to the research collaboration should be clearly explained and justified in the application.

Equality, diversity and inclusion

We are committed to achieving equality of opportunity for all funding applicants. We encourage applications from a diverse range of researchers.

We support people to work in a way that suits their personal circumstances. This includes:

  • career breaks
  • support for people with caring responsibilities
  • flexible working
  • alternative working patterns

Find out more about equality, diversity and inclusion at UKRI.

What we're looking for

Aim

Toxicity issues with advanced therapies (ATs) include, but are not limited to, immune reactions, off-target gene effects, and tumourigenesis. The long-term safety of many advanced therapies remains uncertain, with potential for unexpected toxic effects over time.

Therefore, advancing our understanding of how these therapies can be safely and effectively delivered to patients holds significant potential for breakthroughs, particularly in treating complex and previously untreatable conditions.

This funding opportunity aims to establish core resources and capabilities in advanced therapy toxicology for the UK, fostering connectivity among business, academia, and regulatory bodies, and gaining insights into the biological processes through which ATs can cause harm.

Research into the toxicity of advanced therapies, including the advanced therapy medicinal product (ATMP) classification of cell and gene therapies, regenerative medicine and nucleic acid therapies such as oligonucleotide base therapies and base or gene editing techniques, are all in scope.

Aims include modelling short- and long-term adverse effects and translating research evidence into harmonised standards and definitions of future regulatory pathways.

Additionally, this initiative aims to influence policy and standards in the AT sector and support skills and training in toxicology and regulatory science.

Prosperity Partnerships should aim to address at least one of the following challenge areas in at least one area of advanced therapies:

  • mechanisms governing safety and toxicology of ATs
  • persistence, localisation and distribution of ATs in vivo
  • translation of mechanistic insights into tools and assays, and development of a standardised approach to assessment of safety and toxicology of ATs

For more information on these three challenge areas see the Additional information section.

Prosperity partnerships funded through this initiative will be co-developed with academia and business addressing significant challenge areas in safety and toxicology. These partnerships will form a UK-wide network that goes beyond the individual partnerships, coalescing the field and providing both connectivity and critical mass.

The strategic partnership can be newly established or based on existing, long-term relationships. It should be recognised by both parties and have a clear path for future collaboration, possibly formalised by a memorandum of understanding (MoU) or a collaboration agreement.

The research programme must be co-created, driving shared research challenges, with both business and academic researchers making distinct intellectual contributions.

Scope

Applications should articulate co-developed research programmes addressing clear challenges in safety and toxicology of advanced therapies, and clearly describe the partnership between you, the academic project lead and your lead business project partner (if more than one).

You, as the project lead and your lead business project partner must ensure:

  • there is a demonstrable emerging or established research-based relationship
  • there are clear plans to evolve this relationship via shared research challenges and the prosperity partnership is a key component of the plans to evolve and strengthen this relationship
  • you are both committed to the co-creation of a jointly delivered large scale research programme addressing a clearly defined key challenge area within the funding opportunity remit
  • the lead business project partner (and any other business project partner involved) must commit to matching funding for the prosperity partnership with at least a matched contribution. This must consist of at least 50% in cash with a maximum of 50% of the matched contribution being in-kind.
  • a definitive list of eligible cash contributions, as set out in the ‘Definitive list’ of eligible cash contributions for business leads and partners’ section
  • no UK Research an Innovation (UKRI), public, or government funding will be used as co-investment, and the project lead and the project partner(s) are able to clearly demonstrate an auditable transfer during the grant duration
  • the lead and any other business project partner(s) are from the private sector and therefore driven by profit alternatively from an organisation with a commercial arm which generates independent revenue
  • the lead business project partner is in a position to contribute to the nation’s prosperity through increasing their investment in UK based research and development activities and subsequent product development in the UK

The following is the definitive list of eligible cash contributions by business partners.
We expect the time of researchers, research and innovation associates, technicians, and grant managers to be fully costed onto projects depending on how much time a person would spend on it.

In the application, it is expected that the role and responsibilities of costed persons are detailed, and it is demonstrated clearly how their experience and skills are linked to work packages and outcomes. The appropriateness of the time devoted to the project will be assessed in the panel interview and peer review (at the full application stage).

Gross salary can be claimed as matched funding (that is, including indirect costs such as pension, National Insurance, and taxes) but not business overheads or profits. The salary of a single member of staff (researcher, research and innovation associate or grant manager) can be covered in partnership by the business partner and Medical Research Council (MRC) funds in a ratio that best suits the project.

Below we state the eligible cash contributions for business leads and partners.

Researcher salaries

All or part of the pro rata, gross salary cost associated with researchers employed by research organisations (including project co-leads).

Research and innovation associates’ salaries

All or part of the gross salary cost associated with research associates employed by research organisations to work exclusively on the prosperity partnership.

Research associates can also be employed directly by the businesses in the partnership and the appropriately costed gross salary can be claimed as a cash contribution depending on how much time the person spends on the prosperity partnership.

Professional grant manager salaries

Pro rata gross salary cost of a professional grant manager.

Technician salaries

Pro rata gross salary cost of technicians.

Software licences

New software licences needed for the project and their maintenance cost for the duration of the project. Software licences or intellectual property (IP) owned by the business which are already accessible by the partners will apply at marginal cost, not at market rate.

New equipment

Equipment essential for the successful delivery of the proposed research.

Items of multiple-use equipment (where the equipment is necessary for the pursuit of the proposed research but will not be fully occupied on it) may also be included.

The application must explain the other proposed uses and the overall benefit to MRC research of the equipment.

Equipment produced by the business

Equipment produced by the business is only claimable at the cost of manufacture (not market) rate.

Access to equipment and facilities

Access to specific equipment and facilities critical to achieve the outcomes of the project. If the facility is based at the academic or business partner’s facility, the cash contribution will be valued at cost.

Facilities development

Facilities development can be an eligible business cash contribution if the upgrade will increase the capability of the facilities with specific benefit to the proposed work. This contribution must be justified in addition to any estate costs already factored in. Any facilities development contributions require discussion with us prior to submission.

Business cash contribution

Business cash contributions which will be provided to the academic partners, for the academic partners to manage in line with the project objectives.

Skills and talent training

Skills and training activities such as higher apprenticeships, continuing professional development of the project’s research and innovation team, exchanges, and secondments.

For more information on the background of this funding opportunity, go to the Additional information section.

Duration

The duration of this award is up to a maximum of five years.

Funding available

The full funding amount of £10.5 million will be delivered in a single funding opportunity with programmes being up to five years. The academic full economic cost (FEC) of your programme can be between £2 million and 4 million.

MRC will fund 80% of the FEC and 100% of permitted exceptions.

Find out more about full economic costing.

The business partner(s) must provide at least a matched (financial and in-kind) contribution to the programme.

What we will fund

MRC will fund the academic partner’s costs which can include:

  • staff costs
  • equipment and other items required to carry out the programme
  • costs related to impact
  • travel and subsistence
  • skills and talent training costs

You can also request costs for work to be undertaken at international organisations by international programme co-leads. We will fund 100% of the full economic cost.

The total of such costs requested for international applicants from developed countries (those not on the OECD DAC List of ODA Recipients), India and China must not exceed 30% of the total resources requested.

There is no cap on costs requested for international applicants from DAC list countries.
For more information on international costs and what we will and will not fund see costs we fund and the Collaborate with Researchers in Norway guidance.

What we will not fund

We will not fund:

  • master’s and PhD studentships
  • UK publication costs (publication costs where all the authors are from Low and Middle Income Countries (LMIC)’s can be included)
  • funding to use as a ‘bridge’ between grants

Team project partner

You may include project partners that will support your partnership project through cash or in-kind contributions, such as:

  • staff time
  • access to equipment
  • sites or facilities
  • the provision of data
  • software or materials

Where there is engagement from individuals based in government agencies, international intergovernmental organisations (for example, the World Health Organization), or other stakeholder organisations (for example, industry collaborators) you should include them as a named project partner.

Each project partner must provide a statement of support. If your application involves industry partners, they must provide additional information if the relationship falls within the industry collaboration framework.

Find out more about subcontractors and dual roles.

Who cannot be included as a team project partner

Any individual included in your application with a core team role cannot also be a project partner.

Any organisation that employs a member of the application core team cannot be a project partner organisation. This includes other departments within the same organisation.

If you are collaborating with someone in your organisation, consider including them in the core team as project co-lead or specialist. They cannot be a project partner.

Supporting skills and talent

We encourage you to follow the principles of the Concordat to Support the Career Development of Researchers and the Technician Commitment.

Trusted Research and Innovation (TR&I)

UKRI is committed in ensuring that effective international collaboration in research and innovation takes place with integrity and within strong ethical frameworks. Trusted Research and Innovation (TR&I) is a UKRI work programme designed to help protect all those working in our thriving and collaborative international sector by enabling partnerships to be as open as possible, and as secure as necessary. Our TR&I Principles set out UKRI’s expectations of organisations funded by UKRI in relation to due diligence for international collaboration.

As such, applicants for UKRI funding may be asked to demonstrate how their proposed projects will comply with our approach and expectation towards TR&I, identifying potential risks and the relevant controls you will put in place to help proportionately reduce these risks.

See further guidance and information about TR&I, including where applicants can find additional support.

How to apply

You must be invited to apply to this funding opportunity.

This funding opportunity required applicants to submit an expression of Interest stage which closed on 6 November 2024.

We are running the full funding opportunity on the new UK Research and Innovation (UKRI) Funding Service so please ensure that your organisation is registered. You cannot apply on the Joint Electronic Submissions (Je-S) system. We will publish full details on how to apply when the funding opportunity opens.

The project lead is responsible for completing the application process on the Funding Service, but we expect all team members and project partners to contribute to the application.

Only the lead research organisation can submit an application to UKRI.

If the lead research organisation is an NHS organisation, check it is available in the Funding Service. You are encouraged to check this early as there may be additional steps for the organisation to be set up before you can apply.

To apply

The ‘Start application’ will be emailed to you, following your submission of your successful expression of interest.

  1. Confirm you are the project lead
  2. Sign in or create a Funding Service account. To create an account, select your organisation, verify your email address, and set a password. If your organisation is not listed, email support@funding-service.ukri.org
    Please allow at least 10 working days for your organisation to be added to the Funding Service. We strongly suggest that if you are asking UKRI to add your organisation to the Funding Service to enable you to apply to this Opportunity, you also create an organisation Administration Account. This will be needed to allow the acceptance and management of any grant that might be offered to you.
  3. Answer questions directly in the text boxes. You can save your answers and come back to complete them or work offline and return to copy and paste your answers. If we need you to upload a document, follow the upload instructions in the Funding Service. All questions and assessment criteria are listed in the How to apply section on this Funding finder page.
  4. Allow enough time to check your application in ‘read-only’ view before sending to your research office.
  5. Send the completed application to your research office for checking. They will return it to you if it needs editing.
  6. Your research office will submit the completed and checked application to UKRI.

Where indicated, you can also demonstrate elements of your responses in visual form if relevant. You should:

  • use images sparingly and only to convey important information that cannot easily be put into words
  • insert each new image onto a new line
  • provide a descriptive legend for each image immediately underneath it (this counts towards your word limit)
  • ensure files are smaller than 5MB and in JPEG, JPG, JPE, JFI, JIF, JFIF, PNG, GIF, BMP or WEBP format

Watch our research office webinars about the Funding Service.

For more guidance on the Funding Service, see:

References

Applications should be self-contained, and hyperlinks should only be used to provide links directly to reference information. To ensure the information’s integrity is maintained, where possible, persistent identifiers such as digital object identifiers should be used. Assessors are not required to access links to carry out assessment or recommend a funding decision. Applicants should use their discretion when including references and prioritise those most pertinent to the application.

References should be included in the appropriate question section of the application and be easily identifiable by the assessors for example (Smith, Research Paper, 2019).

You must not include links to web resources to extend your application.

Deadline

MRC must receive your application by 12 February 2025 at 4:00pm UK time.

You will not be able to apply after this time.

Make sure you are aware of and follow any internal institutional deadlines.

Following the submission of your application to the funding opportunity, your application cannot be changed, and applications will not be returned for amendment. If your application does not follow the guidance, it may be rejected.

Personal data

Processing personal data

MRC, as part of UKRI, will need to collect some personal information to manage your Funding Service account and the registration of your funding applications.

We will handle personal data in line with UK data protection legislation and manage it securely. For more information, including how to exercise your rights, read our privacy notice.

Publication of outcomes

MRC, as part of UKRI, will publish the outcomes of this funding opportunity at board and panel.

If your application is successful, we will publish some personal information on the UKRI Gateway to Research.

Summary

Word limit: 550

In plain English, provide a summary we can use to identify the most suitable experts to assess your application.

We usually make this summary publicly available on external-facing websites, therefore do not include any confidential or sensitive information. Make it suitable for a variety of readers, for example:

  • opinion-formers
  • policymakers
  • the public
  • the wider research community

Guidance for writing a summary

Clearly describe your proposed work in terms of:

  • context
  • the challenge the project addresses
  • aims and objectives
  • potential applications and benefits

Core team

List the key members of your team and assign them roles from the following:

  • project lead (PL)
  • project co-lead (UK) (PcL)
  • project co-lead (international) (PcL (I))
  • specialist
  • grant manager
  • professional enabling staff
  • research and innovation associate
  • technician
  • visiting researcher
  • researcher co-lead (RcL)

Only list one individual as project lead, this should be the academic project lead. If you include more than one project lead your application will fail at the checking stage.

Please use the Project Partners section to outline the business project lead and co-leads.

Public contributors should be added to your application under the ‘specialist’ role within the core team (if applicable).

Find out more about UKRI’s core team roles in funding applications.

Application questions

Vision

Word limit: 1,000

What are you hoping to achieve with your proposed work?

What the assessors are looking for in your response

Explain how your proposed work:

  • is of excellent quality and importance within or beyond the field(s) or area(s)
  • has the potential to advance current understanding, or generate new knowledge, thinking or discovery within or beyond the field or area
  • is timely given current trends, context, and needs
  • impacts world-leading research, society, the economy, or the environment

Within this section, we expect you to outline the following:

  • a research vision which should clearly lead to or directly enable a significant step change in knowledge of the safety and toxicity of advanced therapies, developing tools and resources to assess and mitigate safety risks
  • a clearly stated academia/business co-led vision and ambition which identifies why the challenges are ambitious, what the relationship between the academic and industrial partners is, why the academic-business collaboration is essential for success, and why the objectives cannot be achieved by any single partner alone
  • coherence and relevance of the work packages in line with the vision

References may be included within this section.

You may demonstrate elements of your responses in visual form if relevant. Further details are provided in the Funding Service.

Response to feedback

Word limit: 1,000

Provide a response to the feedback your received at the Expression of Interest stage.

Please ensure you describe how previous feedback has been considered and addressed.

You may demonstrate elements of your responses in visual form if relevant. Further details are provided in the Funding Service.

Approach

Word limit: 2,500

How are you going to deliver your proposed work?

What the assessors are looking for in your response

Explain how you have designed your approach so that it:

  • is effective and appropriate to achieve your objectives
  • is feasible, and comprehensively identifies any risks to delivery and how they will be managed
  • uses a clearly written and transparent methodology (if applicable)
  • summarises the previous work and describes how this will be built upon and progressed (if applicable)
  • will maximise translation of outputs into outcomes and impacts
  • describes how your, and your team’s, research environment (in terms of the place and relevance to the project) will contribute to the success of the work

Within this section, we expect you to address the following:

  • the response should outline in detail the science and innovation to be undertaken throughout the proposed project and clearly demonstrate the methodology intended to be used in order to attain the objectives
  • the response should explain how appropriate and feasible this is for the programme of work, while also considering responsible research and innovation
  • the response should set the proposed research in the context of the current state of knowledge, other work underway in the field, and how the research partnership might be relevant to national and international strategy or policy
  • a workplan which should cover the first one to two years of the project in detail with broader aims of the full length of the project and indicate appropriate decision points that would influence the direction of the research. The workplan should also describe any interdependencies between or within work packages.
  • explain and justify the inclusion of public partnerships (if applicable) and the added value these offer
Contextual information

Given the nature of the prosperity partnership programme, it is essential to include contextual information outlining the potential to advance the safety of Advanced Therapies and how this collaboration will lead to academic and industrial benefits. The reviewers will be asked to focus on the research programme, methodology, feasibility, the associated technical detail, and the justification of the broader benefits from the partnership.

The following headings should be used in your response:

  • background
  • research hypothesis and objectives
  • research programme and methodology
  • work plan
  • academic and industrial outcomes, and benefits

You are expected to include a workplan and a project Gannt chart in this section. A project Gannt chart is compulsory and should be inserted as an image at the very end of this section. The Gannt chart should identify appropriate deliverables, responsibilities, and interdependencies.

We understand that there may be some flexibility within the project so plans must be covered in detail for the first one to two years of the programme. The plan should reference the management and governance strategy, highlight relevant KPIs, as well as refer to the monitoring and evaluation framework where relevant.

References may be included within this section.

You may demonstrate elements of your responses in visual form if relevant. You may include images, graphs, tables. Further details are provided in the Funding Service.

Applicant and team capability to deliver

Word limit: 1,650

Why are you the right individual or team to successfully deliver the proposed work?

What the assessors are looking for in your response

Evidence of how you, and if relevant your team, have:

  • the relevant experience (appropriate to career stage) to deliver the proposed work
  • the right balance of skills and expertise to cover the proposed work
  • the appropriate leadership and management skills to deliver the work and your approach to develop others
  • contributed to developing a positive research environment and wider community

Within this section we expect you to:

  • outline how the team’s skills and expertise as a whole relate to the delivery of the project’s vision and ambition, and how these will directly contribute to the realisation of proposed outcomes and wider benefits
  • provide evidence and demonstrate the additionality and added-value the business partner(s) will bring to the team in relation to the delivery of the projects work packages and vision

You may demonstrate elements of your responses in visual form if relevant. Further details are provided in the Funding Service.

The word limit for this section is 1,650 words: 1,150 words to be used for R4RI modules (including references) and, if necessary, a further 500 words for Additions.

Use the Résumé for Research and Innovation (R4RI) format to showcase the range of relevant skills you and, if relevant, your team (project and project co-leads, researchers, technicians, specialists, partners and so on) have and how this will help deliver the proposed work. You can include individuals’ specific achievements but only choose past contributions that best evidence their ability to deliver this work.

Complete this section using the R4RI module headings listed. Use each heading once and include a response for the whole team, see the UKRI guidance on R4RI. You should consider how to balance your answer, and emphasise where appropriate the key skills each team member brings:

  • contributions to the generation of new ideas, tools, methodologies, or knowledge
  • the development of others and maintenance of effective working relationships
  • contributions to the wider research and innovation community
  • contributions to broader research or innovation users and audiences and towards wider societal benefit
Additions

Provide any further details relevant to your application. This section is optional and can be up to 500 words. You should not use it to describe additional skills, experiences, or outputs, but you can use it to describe any factors that provide context for the rest of your R4RI (for example, details of career breaks if you wish to disclose them).

Complete this as a narrative. Do not format it like a CV.

References may be included within this section.

UKRI has introduced new role types for funding opportunities being run on the new Funding Service.

For full details, see Eligibility as an individual.

Governance

Word limit: 1,000

How will you manage the award to successfully deliver its objectives?

What the assessors are looking for in your response

Explain how the proposed award will be managed, demonstrating that it:

  • will be effectively governed, including details about advisory structures
  • will be effectively and inclusively managed, demonstrated by a clear management plan
  • has clear leadership team roles and responsibilities
  • will manage and encourage partnerships with non-HEI organisations across government, industry and civil society
  • has plans for monitoring your progress as well as self-evaluation throughout the lifetime of your award

You may demonstrate elements of your responses in visual form if relevant. Further details are provided in the Funding Service.

Opportunity and market analysis

Word limit: 1,000

What is the opportunity you are looking to exploit or what challenge will your project address?

What the assessors are looking for in your response

Explain how your proposed work:

  • has the potential to address a business need or technological challenge in the safety and toxicology of Advanced Therapies (ATs)
  • is timely given current trends and context
  • meets the needs of potential users or customers and has potential to feed into the regulatory landscape
  • is resilient to changing external circumstances and consumer behaviours
  • impacts society, the economy or the environment

Within this section we also expect you to:

  • identify the potential direct or indirect benefits and who the beneficiaries might be
  • outline capabilities to extract valuable insights that will support the development of robust regulatory frameworks in the field of advanced therapies safety and toxicity
  • detail the broader business, academic, economic, and societal benefits that will be derived from this initiative. These include fostering innovation across sectors, strengthening the UK’s global leadership in ATs, developing and retaining multidisciplinary talent, and ultimately improving public health outcomes.

Additionality and added value

Word limit: 300

What is the additionality and added value?

What the assessors are looking for in your response

The panel will consider the extent to which the proposed work demonstrates:

  • evidence of the additionality and added value of a prosperity partnership in comparison to other funding opportunities
  • clear evidence of the buy-in from business partners and co-creation of the proposed business-inspired fundamental research programme

Within this section, we expect you to consider:

  • the aspects where this type of funding provides added value that no other scheme does

Intellectual property (IP) management and communication

Word limit: 700

What is your IP exploitation plan?

What the assessors are looking for in your response

Evidence of your plans to:

  • manage the outputs of the project, including any intellectual assets and intellectual property between the academic and business partners
  • have freedom to operate
  • protect the foreground IP or market position
  • disseminate and communicate the outputs of your project
  • access potential future investments, if required

Project partners

Add details about any project partners’ contributions.

A project partner is the collaborating business-led organisation who will have an integral role in the prosperity partnership. This may include direct (cash) or indirect (in-kind) contributions such as expertise, staff time or use of facilities.

Important note: As your application will include industry project partners, you will need to complete the Industry Collaboration Framework (ICF) section. Find out more about ICF.

You must ensure that any third-party individual or organisation you include within the Funding Service as a project partner, also provides you with a supporting email or letter of support (see next section ‘Project partners: letters or emails of support’).

The individual named as the project partner contact, cannot be included in your application as a member of the core team, in any core team role.

The project partner organisation cannot be an applicant organisation, where any member of the core team is based. For example, you cannot include a different department based within the applicant organisation as a project partner.

If an individual or organisation outside the core team is responsible for recruitment of people as research participants or providing human tissue for this project, list them as a project partner.

Add the following project partner details:

  • the organisation name (searchable via a drop-down list or enter the organisation’s details manually, as applicable)
  • the project partner contact name and email address
  • the type of contribution (direct or in-direct) and its monetary value

If there are specific circumstances where project partners do require funding for minor costs such as travel and subsistence, these project partner costs should be claimed and justified within the resources and costs section of your application.

If a detail is entered incorrectly and you have saved the entry, remove the specific project partner record and re-add it with the correct information.

For audit purposes, UKRI requires formal collaboration agreements to be put in place if an award is made.

Project partners: letters (or emails) of support

Word limit: 10

Upload a single PDF containing the letters or emails of support from each partner you named in the ‘Project partners’ section. These should be uploaded in English or Welsh only.

What the assessors are looking for in your response

Enter the words ‘attachment supplied’ in the text box.

What supporting statements we are looking for

Important note: We are only looking for you to provide project partner letters or emails of support from the following:

  • a third party individual
  • a third party organisation

Third party means the individual and organisation must not be involved in the application core team. You must ensure that any project partners providing a supporting document, are also added to the ‘Project partners’ section within the Funding Service.

What supporting statements we are not looking for

We are not looking for you to provide any letters or emails of support from individuals or organisations included in your application core team (this includes other departments within the same organisation). Any individual or organisation included in your application with a core team role cannot also be a project partner.

Do not include any other statements or any other type of information we have not requested, including letter or emails of support from colleagues simply expressing supportive opinions. We only expect letters or emails of support from your third party project partners uploaded to this section.

If you include any information not requested by MRC, your application will be rejected.

Supporting letter and email guidance for third party project partners

Each project partner letter or email you provide should:

  • confirm the partner’s commitment to the project
  • clearly explain the value, relevance, and possible benefits of the work to them
  • describe any additional value that they bring to the project
  • include the name of the project partner organisation and contact information (this should match the partner contact and organisation name details you must add to the ‘Project partners’ section)
  • have a page limit of two sides of A4 per partner

Project partners letters and emails of support are not required to be on headed paper or include handwritten signatures (electronic signatures are acceptable from the nominated partner contact).

Industry or company project partner letter and email of support guidance

Industry or company project partners are required to complete the industry or company letter of support template by exploring the document download section of MRC Industry Collaboration Framework (ICF) This will ensure the letter or email they provide you, contains all the relevant information we need.

The letter should provide a breakdown of the project partners’ contributions to the project including how they fit under ‘cash’ and ‘in kind’ contribution headings. For the definitive list of eligible cash contributions please see the Aim section of the funding finder.

Project partner responsibility for the recruitment of people

If the project partner is responsible for the recruitment of people as research participants or providing human tissue their letter or email of support should include:

  • agreement that the project partner will recruit the participants or provide tissue
  • confirmation that what is being supplied is suitable for the proposed work
  • confirmation that the quantity of tissue being supplied is suitable, but not excessive for achieving meaningful results (if applicable)
Multiple project partners

If you have multiple project partners, you should:

  • ensure each separate partner letter or email of support, does not exceed two pages of A4
  • consolidate all the supporting documents provided by each project partner into a single PDF file before uploading
  • ensure the PDF does not exceed the maximum file size of 8MB

The Funding Service will provide document upload details when you apply.

If you do not have any project partners, you will be able to indicate this in the Funding Service.

Ensure you have prior agreement from project partners so that, if you are offered funding, they will support your project as indicated in the ‘Project partners’ section.

For audit purposes, UKRI requires formal collaboration agreements to be put in place if an award is made.

Industry Collaboration Framework (ICF)

Word limit: 1,500

Does your application include collaboration with industry or company project partners?

What the assessors are looking for in your response

The assessors are looking for you to confirm if your proposed work involves collaboration with an industry or company project partner. If it does, you will need to follow the MRC industry collaboration framework (ICF).

By ‘industry or company’ we mean an enterprise that puts or has intention to put goods or services on a market.

For guidance to assist your decision if your proposed work requires you to follow ICF, you should explore the ICF decision tree and find out more about ICF which includes:

  • collaboration agreements
  • definitions of basic or applied research
  • internationally based companies
  • subsidy control
  • intellectual property (IP) arrangements
  • fully flexible and gated contributions
  • the ICF assessment criteria

Enter ‘Yes’ in the text box if you have industry or company project partners and you are likely to follow ICF. You should also confirm your answers to the ICF questions one to nine in the text box for each ICF project partner.

Contact prosperitypartnerships@mrc.ukri.org if you are unsure if your application should follow ICF.

In addition to the project partner information completed in the previous section, the assessors are looking for information relating to the nature, goals and conditions of the collaboration and any restrictions or rights to the project results that could be claimed by the industry or company project partner.

Confirm your answers to the ICF questions in the text box, repeat this process for each ICF project partner:

  1. Name the industry or company project partner considered under ICF.
  2. Indicate whether your application is basic research or applied research.
  3. Explain why, in the absence of the requested UKRI funding, the collaboration and the planned research could not be undertaken.
  4. State whether your application is under the category of fully flexible contribution or gated contribution (based on the IP sharing arrangements with the industry or company).
  5. Outline the pre-existing IP (‘background IP’) that each partner, including the academic partner, will bring to the collaborative research project and the terms under which partners may access these assets.
  6. Outline the IP that is expected to be developed during the collaborative research project (‘foreground IP’) and briefly outline how it will be managed, including:
    • who will own this IP
    • what rights industry or company partners will have to use academically-generated foreground IP during and after the research project, for internal research and development or for commercial purposes
    • any rights of the academic partner to commercialise the foreground IP, including foreground IP generated by industry or company partners
  7. Outline any restrictions to dissemination of the project results, including the rights of the industry or company partner to:
    • review, approve or delay publications (including the time period associated with such rights)
    • request or require the removal of any information
  8. Declare any conflicts of interest held by the applicants in relation to the industry or company project partners and describe how they will be managed.
  9. Justify collaborating with an overseas industry or company under ICF (if applicable).

Failure to provide the information requested for industry or company partners under ICF could result in your application being rejected.

You are recommended to discuss the goals and conditions of any collaboration with an industry or company with your technology transfer or contracts office before applying.

For audit purposes, UKRI requires formal collaboration agreements to be put in place if an award is made. You must provide us with a copy of the collaboration agreement, signed by all partners, before an ICF award starts.

If this does not apply to your proposed work, you will be able to indicate this in the Funding Service

Trusted Research and Innovation

Word limit: 100

Does the proposed work involve international collaboration in a sensitive research or technology area?

What the assessors are looking for in your response

Demonstrate how your proposed international collaboration relates to Trusted Research and Innovation, including:

  • list the countries your international project co-leads, project partners and visiting researchers, or other collaborators are based in
  • if international collaboration is involved, explain whether this project is relevant to one or more of the 17 areas of the UK National Security and Investment (NSI) Act
  • if one or more of the 17 areas of the UK National Security and Investment (NSI) Act are involved list the areas

If your proposed work does not involve international collaboration, you will be able to indicate this in the Funding Service.

We may contact you following submission of your application to provide additional information about how your proposed project will comply with our approach and expectation towards TR&I, identifying potential risks and the relevant controls you will put in place to help manage these risks.

Facilities

Word limit: 250

Does your proposed research require the support and use of a facility?

What the assessors are looking for in your response

If you will need to use a facility, follow your proposed facility’s normal access request procedures. Ensure you have prior agreement so that if you are offered funding, they will support the use of their facility on your project.

For each requested facility you will need to provide the:

  • name of facility, copied and pasted from the facility information list (DOCX, 35KB)
    proposed usage or costs, or costs per unit where indicated on the facility information list
  • confirmation you have their agreement where required

Facilities should only be named if they are on the facility information list above. If you will not need to use a facility, you will be able to indicate this in the Funding Service.

Data management and sharing

Word limit: 1,500

How will you manage and share data collected or acquired through the proposed research?

What the assessors are looking for in your response

Provide a data management plan which should clearly detail how you will comply with MRC’s published data management and sharing policies, which includes detailed guidance notes.

Provide your response in the text box following the headings in the MRC data management plan template. You are not required to upload the document to your application.

The length of your plan will vary depending on the type of study being undertaken, as follows:

  • population cohorts, longitudinal studies, genetic, omics and imaging data, biobanks, and other collections that are potentially a rich resource for the wider research community: maximum of 1,500 words
  • all other research, less complex, the plan may be as short as 500 words

Ethics and responsible research and innovation (RRI)

Word limit: 500

What are the ethical or RRI implications and issues relating to the proposed work?  If you do not think that the proposed work raises any ethical or RRI issues, explain why.

What the assessors are looking for in your response

Demonstrate that you have identified and evaluated:

  • the relevant ethical or responsible research and innovation considerations
  • how you will manage these considerations

Consider the MRC guidance on ethics and approvals.

You may demonstrate elements of your responses in visual form if relevant. Further details are provided in the Funding Service.

Genetic and biological risk

Word limit: 700

Does your proposed research involve any genetic or biological risk?

What the assessors are looking for in your response

In respect of animals, plants or microbes, are you proposing to:

  • use genetic modification as an experimental tool, like studying gene function in a genetically modified organism
  • release genetically modified organisms
  • ultimately develop commercial and industrial genetically modified outcomes

If yes, provide the name of any required approving body and state if approval is already in place. If it is not, provide an indicative timeframe for obtaining the required approval.

Identify the organism or organisms as a plant, animal or microbe and specify the species and which of the three categories the research relates to.

Identify the genetic and biological risks resulting from the proposed research, their implications, and any mitigation you plan on taking. Assessors will want to know you have considered the risks and their implications to justify that any identified risks do not outweigh any benefits of the proposed research.

If this does not apply to your proposed work, you will be able to indicate this in the Funding Service.

Research involving the use of animals

Word limit: 10

Does your proposed research involve the use of vertebrate animals or other organisms covered by the Animals Scientific Procedures Act?

What the assessors are looking for in your response

If you are proposing research that requires using animals, download and complete the Animals Scientific Procedures Act template (DOCX, 74KB), which contains all the questions relating to research using vertebrate animals or other Animals (Scientific Procedures) Act 1986 regulated organisms.

Save it as a PDF. The Funding Service will provide document upload details when you apply. If this does not apply to your proposed work, you will be able to indicate this in the Funding Service.

Conducting research with animals overseas

Word limit: 700

Will any of the proposed animal research be conducted overseas?

What the assessors are looking for in your response

If you are proposing to conduct overseas research, it must be conducted in accordance with welfare standards consistent with those in the UK, as in Responsibility in the use of animals in bioscience research, page 14. Ensure all named applicants in the UK and overseas are aware of this requirement.

If your application proposes animal research to be conducted overseas, you must provide a statement in the text box. Depending on the species involved, you may also need to upload a completed template for each species listed.

Statement

Provide a statement to confirm that:

  • all named applicants are aware of the requirements and have agreed to abide by them
    this overseas research will be conducted in accordance with welfare standards consistent with the principles of UK legislation
  • the expectation set out in Responsibility in the use of animals in bioscience research will be applied and maintained
  • appropriate national and institutional approvals are in place
Templates

Overseas studies proposing to use non-human primates, cats, dogs, equines or pigs will be assessed during NC3Rs review  of research applications. Provide the required information by completing the template from the question ‘Research involving the use of animals’.

For studies involving other species, select, download, and complete the relevant Word checklist or checklists from this list:

Explore NC3Rs checklist for the use of animals overseas

Save your completed template as a PDF and upload to the Funding Service. If you use more than one checklist template, save it as a single PDF.

The Funding Service will provide document upload details when you apply.

If conducting research with animals overseas does not apply to your proposed work, you will be able to indicate this in the Funding Service.

Research involving human participation

Word limit: 700

Will the project involve the use of human subjects or their personal information?

What the assessors are looking for in your response

If you are proposing research that requires the involvement of human subjects, provide the name of any required approving body and whether approval is already in place.

Justify the number and the diversity of the participants involved, as well as any procedures.

Provide details of any areas of substantial or moderate severity of impact.

If this does not apply to your proposed work, you will be able to indicate this in the Funding Service.

Research involving human tissues or biological samples

Word limit: 700

Does your proposed research involve the use of human tissues, or biological samples?

What the assessors are looking for in your response

If you are proposing work that involves human tissues or biological samples, provide the name of any required approving body and whether approval is already in place.

Justify the use of human tissue or biological samples specifying the nature and quantity of the material to be used and its source.

If this does not apply to your proposed work, you will be able to indicate this in the Funding Service.

Resources and cost justification

Word limit: 1,200

What will you need to deliver your proposed work and how much will it cost?

What the assessors are looking for in your response

Justify the application’s more costly resources, in particular:

  • project staff
  • significant travel for field work or collaboration (but not regular travel between collaborating organisations or to conferences)
  • any equipment that will cost more than £10,000
  • any consumables beyond typical requirements, or that are required in exceptional quantities
  • all facilities and infrastructure costs
  • all resources that have been costed as ‘Exceptions’
  • support for public and patient involvement and engagement. Costs for public partnerships including payments to public partners can be included under the exceptions fund heading
  • support for preserving, long-term storage, or sharing of data
  • support for international co-leads, demonstrating this is within the 30% costs cap for co-leads from high-income countries, India and China. There is no cap on costs requested for international applicants from DAC list countries
  • NHS research costs, when they are associated with NHS studies
  • animal costs, such as numbers that need to be bred or maintained and to maintain high welfare standards

Within this section we expect you to demonstrate that:

  • the resources requested are credible and appropriate in terms of meeting the needs of the scientific research programme
  • the resources requested are sufficient to deliver the stated vision and ambition of the programme including any relevant training, the realisation of the outlined benefits, and delivery of impact to the UK

Assessors are not looking for detailed costs or a line-by-line breakdown of all project resources. Overall, they want you to demonstrate how the resources you anticipate needing for your proposed work:

  • are comprehensive, appropriate, and justified
  • represent the optimal use of resources to achieve the intended outcomes
  • maximise potential outcomes and impacts

Clinical research using NHS resources

Word limit: 250

Are you applying to do clinical research in the UK?

What the assessors are looking for in your response

Researchers applying to do clinical research in the NHS, public health or social care usually need to complete a Schedule of Events Cost Attribution Tool (SoECAT).

We request the SoECAT because we want to know that you have taken the appropriate steps to request National institute for Health and Care Research (NIHR) support and for the full costs of your research to be attributed, calculated and paid.

We want to see the expected total resources required for your project to consider if these are appropriate.

Enter ‘Yes’ and complete and upload a SoECAT if you are applying for clinical research and:

  • you will carry out your research in the UK
  • your research will use NHS resources
  • the research requires approval by Health Research Authority (England) or its equivalents in Northern Ireland, Scotland or Wales
  • you will need support from the NIHR Research Delivery Network, this may include studies in a social care or public health setting

It is important to complete a SoECAT to be eligible for NIHR support You must complete a SoECAT even if you do not think your clinical research will involve excess treatment costs (ETCs).

See MRC guidance on who needs to complete a SoECAT.

How to complete a SoECAT

SoECAT guidance can be found on the NIHR website.

These are the steps you need to take:

  1. Contact an attributing the costs of health and social care Research & Development (AcoRD) specialist as early as possible in the application process
  2. Complete an online SoECAT. Excel versions of the form have been discontinued. If you do not have an account for NIHR’s Central Portfolio Management System (CPMS) you will need create and activate one. See the user guide for instructions
  3. Request authorisation of your SoECAT
  4. Once authorised extract the ‘study information’ and the ‘summary’ page from the ‘Funder Export’, combine them as a single PDF and upload it to your application.

Applications that require a SoECAT but have not uploaded the SoECAT funder export study information and summary may be rejected.

Ensure the AcoRD specialists name and date are included within the uploaded summary page. The SoECAT is invalid without this information.

Contact prosperitypartnerships@mrc.ukri.org if you have questions about the UKRI aspects of this process or have concerns that your SoECAT may not be authorised in time for the application closing date.

If this does not apply to your proposed work, you will be able to indicate this in the Funding Service.

How we will assess your application

Assessment process

We will assess your application using the following process:

  • a mandatory expression of interest (EOI) stage – you must pass this stage to be eligible for the current application stage
  • a full application stage (current stage): involves a review and shortlisting process by an expert panel, which will shortlist applications for the final interview stage
  • an interview stage: conducted by an expert panel who will make a funding recommendation to Medical Research Council (MRC)

Full application stage assessment and interview

Full stage applications will be assessed during a shortlisting meeting, where a subset of applicants will be shortlisted for the final interview stage. In this final stage, an expert panel will evaluate both the quality of the full application and the applicant’s performance during the interview. The panel will then make a funding recommendation.

We expect interviews to be held on 28 or 29 April 2025.

Principles of assessment

We support the San Francisco declaration on research assessment and recognise the relationship between research assessment and research integrity.

Find out about the UKRI principles of assessment and decision making.

We reserve the right to modify the assessment process as needed.

Evaluation areas

Applications will be examined for their fit to the scope and remit of the funding opportunity using the following evaluation areas:

  • vision: the extent to which the proposed work will achieve transformative impacts through a strong, co-developed vision, with clear short-term and medium-term benefits. Assessors will evaluate the potential and timeliness of the work, its alignment with the opportunity aims, and its capacity to impact research, society, and the economy
  • additionality and added value: the unique added value and benefits of the prosperity partnership, including evidence of business partner buy-in and co-creation of the proposed research programme
  • applicant and team capability to deliver: the leadership and team structure, including evidence of effective collaboration between business and academic programme leads where appropriate, and potential to manage a large, complex programme with diverse stakeholders

Assessment areas

The assessment areas we will use are:

  • vision of the project
  • approach of the project (including data management)
  • capability of the applicant or applicants and the project team to deliver the project
  • additionality and added value
  • ethical and responsible research and innovation considerations of the project
  • resources requested to do the project

Find details of assessment questions and criteria under the ‘Application questions’ heading in the ‘How to apply’ section.

Contact details

Get help with your application

If you have a question and the answers aren’t provided on this page

Important note: The Helpdesk is committed to helping users of the UK Research and Innovation (UKRI) Funding Service as effectively and as quickly as possible. In order to manage cases at peak volume times, the Helpdesk will triage and prioritise those queries with an imminent opportunity deadline or a technical issue. Enquiries raised where information is available on the Funding Finder opportunity page and should be understood early in the application process (for example, regarding eligibility or content/remit of an opportunity) will not constitute a priority case and will be addressed as soon as possible.

Contact details

For help and advice on costings and writing your proposal please contact your research office in the first instance, allowing sufficient time for your organisation’s submission process.

For questions related to this specific funding opportunity please contact prosperitypartnerships@mrc.ukri.org

Any queries regarding the system or the submission of applications through the Funding Service should be directed to the helpdesk.

Email: support@funding-service.ukri.org
Phone: 01793 547490

Our phone lines are open:

  • Monday to Thursday 8:30am to 5:00pm
  • Friday 8:30am to 4:30pm

To help us process queries quicker, we request that users highlight the council and opportunity name in the subject title of their email query, include the application reference number, and refrain from contacting more than one mailbox at a time.

For further information on submitting an application.

Sensitive information

If you or a core team member need to tell us something you wish to remain confidential, email prosperitypartnerships@mrc.ukri.org

Include in the subject line: [the funding opportunity title; sensitive information; your Funding Service application number].

Typical examples of confidential information include:

  • individual is unavailable until a certain date (for example due to parental leave)
  • declaration of interest
  • additional information about eligibility to apply that would not be appropriately shared in the ‘Applicant and team capability’ section
  • conflict of interest for UKRI to consider in reviewer or panel participant selection
  • the application is an invited resubmission

For information about how UKRI handles personal data, read UKRI’s privacy notice.

Additional info

Background

The Medial Research Council (MRC) is committed to supporting the development, scale-up, and delivery of Advanced Therapies (ATs) to patients. This initiative leverages MRC’s longstanding investment in toxicology and AT to facilitate the translation of discovery science into clinically relevant outcomes and to enhance skills in regulatory science for ATs.

Current safety and toxicological assessments do not adequately address novel medicines like ATs, restricting innovation and patient benefit. To overcome these limitations, three interconnected focus areas are needed:

  • understanding the mechanisms influencing the safety and toxicity of ATs
  • monitoring their persistence, localisation, and interactions in vivo
  • developing tools and assays to translate these findings into clinically relevant outcomes

Mechanisms governing safety and toxicology of ATs

A greater understanding of factors affecting safety and toxicology of ATs is needed. The recent demonstration of unexpected out-of-frame peptides by RNA-based medicines highlights the potential risk that insufficient safety assessment of these novel therapies presents, and therefore the need for more in-depth understanding.

ATs typically persist in the human body for considerably longer timeframes than traditional medicines, for example, small molecules, and so understanding the pharmacokinetic (PK) and pharmacodynamic (PD) effects is critical but extremely challenging where the PK/PD of ATs is therapy, patient-specific, donor-specific or both and not reflected well by preclinical models.

Not all conventional pharmacokinetic parameters (for example, absorption, distribution, metabolism and excretion) apply to advanced therapies or are sufficient to assess their safety. The safety and pharmacokinetics of cell therapies can be affected by factors such as recognition of healthy tissue, graft failure, graft versus host disease (GVHD), oncogenic potential or donor-related product attributes, migration from the target site (localised treatments), ectopic tissue formation (stem-cell derived products), replication and triggering of unwanted immune responses.

For gene therapies and gene editing techniques, there is a risk of random gene integration or unintended mutations. The consequences of these risks are not yet fully understood, but off-target gene editing can introduce mutations that may lead to tumourigenicity or uncontrolled cell growth, raising significant safety concerns.

Although the toxicity profiles of gene and nucleic acid (NA) therapies have improved over the past decade, some therapies still pose risks of liver and kidney toxicity, which remains inadequately understood.

There is a need for more advanced and predictive in vitro and in vivo studies to better assess the risks of toxicity and tumourigenicity. Additionally, a deeper understanding of the types of mutations resulting from gene editing and their potential risks in gene and cell therapy products is necessary to establish acceptable limits within mutagenic profiles. For nucleic acid therapies, such as antisense oligonucleotides, safety is sequence-dependent, yet there is limited knowledge about how sequence changes or conjugation to delivery moieties affect their safety profiles.

For viral vectors, addressing the risk of inadvertent germline transmission or viral shedding is crucial. Concerns about genomic integration of vectors, including those like Adeno-associated virus which are generally considered non-integrating, pose risks that could undermine the success of these treatments.

Additional toxicities include integration-site specific hazards, immunotoxicity, and for CAR-T cells, acute on-target/off-tumour, off-target, and neurological toxicities. A better understanding of therapeutic thresholds, especially in CAR-T therapies, is essential and could be enhanced through improved modeling to determine tolerable levels of on-target/off-tumour toxicity.

While mitigation strategies exist to reduce patient toxicity risks, clinical and preclinical safety approaches need to be strengthened, and knowledge should be shared across the AT landscape.

For all ATs, validated predictive biomarkers for toxicity of treatments remain essential to ensure greater and safer uptake. Linking human based in vitro systems with clinical expertise and patient organisations is key to achieving these outcomes.

Persistence, localisation and distribution of ATs in vivo

The disposition and persistence of any therapeutic product must be understood before administering the first dose to humans. This is essential in all AT development, as even a single dose of an AT can persist for months or years, and gene therapy products could potentially remain in the body for life. The persistence of cell therapies can vary between patients, necessitating real-time monitoring.

A shortage of appropriate model systems and techniques to study the localisation of ATs over time in vivo is a major barrier to their development. Development of suitable imaging technologies to track and monitor ATs would therefore be advantageous.

The sector needs more physiologically relevant large animal models, including pig and sheep, as well as access to suitable facilities to perform these experiments.

Development of agreed model systems and knowledge sharing across the sector is key to proactively streamlining the regulatory pathway.

Translation of mechanistic insights into tools and assays, and development of a standardised approach to assessment of safety and toxicology

It is critical for the field to generate underpinning biological evidence that will improve patient safety and enhance regulatory decision-making across product lifecycles, supporting policy formulation and enabling agile and proportionate regulation.
The more permissive regulatory system in the UK continues to be a benefit to AT development, however, there is room for improvement with potential for streamlining. Indeed, there is an increasing focus by the Medicines and Healthcare products Regulatory Agency (MHRA) on promoting regulatory science.

There are opportunities to work with the agency for mutual benefit to generate essential reference standards needed by academia and business alike, and to streamline and actively promote the translational and regulatory path. Connecting these insights with regulatory experts and recent Innovate UK investment in Regulatory Innovation Networks would be beneficial.

Overall, this investment in the safety and toxicology of ATs aims to create a robust framework that ensures these innovative treatments are safe and effective. This involves building a strong foundation in toxicology research, fostering collaboration across sectors, and continuously improving safety assessments to keep pace with advancements in therapeutic technologies.

Research and innovation impact

Impact can be defined as the long-term intended or unintended effect research and innovation has on society, economy and the environment; to individuals, organisations, and the wider global population.

Additional disability and accessibility adjustments

UKRI can offer disability and accessibility support for UKRI applicants and grant holders during the application and assessment process if required.

Webinar

MRC hosted a webinar on 10 October, providing an overview of the aims and objectives of this funding opportunity, a description of the application process, and a Q&A session.

Watch a recording of the webinar via Zoom.

Research disruption due to COVID-19

We recognise that the COVID-19 pandemic has caused major interruptions and disruptions across our communities. We are committed to ensuring that individual applicants and their wider team, including partners and networks, are not penalised for any disruption to their career, such as:

  • breaks and delays
  • disruptive working patterns and conditions
  • the loss of ongoing work
  • role changes that may have been caused by the pandemic

Reviewers and panel members will be advised to consider the unequal impacts that COVID-19 related disruption might have had on the capability to deliver and career development of those individuals included in the application. They will be asked to consider the capability of the applicant and their wider team to deliver the research they are proposing.

Where disruptions have occurred, you can highlight this within your application if you wish, but there is no requirement to detail the specific circumstances that caused the disruption.

Updates

  • 1 November 2024
    Webinar recording for 10 October 2024 added in 'Additional info'
  • 18 October 2024
    Updated expression of interest template added in 'How to apply' and 'Additional info'

This is the website for UKRI: our seven research councils, Research England and Innovate UK. Let us know if you have feedback or would like to help improve our online products and services.